使用贝叶斯方法增强重症试验解读:理论概述与急性呼吸窘迫综合征肺泡复张试验的示例再分析
本文为重症医学视角的方法学文章,讨论频率学派与贝叶斯方法在临床试验分析中的差异,指出P值仅反映数据与零假设的不兼容性,不等同于无获益证据。贝叶斯方法产生与观察数据兼容的效应量分布,结合研究者选择的先验(反映既有信念和既往实证证据)计算临床获益的可能性。作者以急性呼吸窘迫综合征肺泡复张试验为例进行贝叶斯再分析演示,并提出选择先验的框架,同时指出若先验未事先定义则存在构造偏倚结果的风险,建议重症社区对先验进行一定标准化。
要点
- P值仅提供数据与零假设不兼容的证据,不能直接证明备择假设,可能导致将无证据误读为无获益证据。
- 贝叶斯再分析产生与试验数据兼容的效应量分布,结合先验计算临床获益的可能性,可补充频率学派解读。
- 先验由研究者选择以反映对干预效果的既有信念和既往实证证据,须事先定义以避免偏倚结果。
- 作者以急性呼吸窘迫综合征肺泡复张试验为例演示贝叶斯再分析,并提出选择先验的框架。
- 作者认为重症社区可能需要对贝叶斯再分析的先验进行一定标准化。
研究设计与关键结果
- 本文为方法学文章,讨论频率学派与贝叶斯方法在临床试验分析中的差异,介绍贝叶斯再分析框架并以急性呼吸窘迫综合征肺泡复张试验为例进行再分析演示。
证据类型、等级与局限
- 证据类型:方法学文章(重症医学视角)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对P值大于传统阈值0.05但效应估计看似有临床意义的试验,作者提出可用贝叶斯再分析提供临床获益的概率解释。
- 作者认为先验须事先定义,否则存在构造出产生偏倚结果的先验的风险。
- 作者认为重症社区可能需要对贝叶斯再分析的先验进行一定标准化。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Most randomized trials are designed and analyzed using frequentist statistical approaches such as null hypothesis testing and P values. Conceptually, P values are cumbersome to understand, as they provide evidence of data incompatibility with a null hypothesis (e.g., no clinical benefit) and not direct evidence of the alternative hypothesis (e.g., clinical benefit). This counterintuitive framework may contribute to the misinterpretation that the absence of evidence is equal to evidence of absence and may cause the discounting of potentially informative data. Bayesian methods provide an alternative, probabilistic interpretation of data. The reanalysis of completed trials using Bayesian methods is becoming increasingly common, particularly for trials with effect estimates that appear clinically significant despite P values above the traditional threshold of 0.05. Statistical inference using Bayesian methods produces a distribution of effect sizes that would be compatible with observed trial data, interpreted in the context of prior assumptions about an intervention (called "priors"). These priors are chosen by investigators to reflect existing beliefs and past empirical evidence regarding the effect of an intervention. By calculating the likelihood of clinical benefit, a Bayesian reanalysis can augment the interpretation of a trial. However, if priors are not defined a priori, there is a legitimate concern that priors could be constructed in a manner that produces biased results. Therefore, some standardization of priors for Bayesian reanalysis of clinical trials may be desirable for the critical care community. In this Critical Care Perspective, we discuss both frequentist and Bayesian approaches to clinical trial analysis, introduce a framework that researchers can use to select priors for a Bayesian reanalysis, and demonstrate how to apply our proposal by conducting a novel Bayesian trial reanalysis.
参考来源
- Zampieri FG, Casey JD, Shankar-Hari M, et al. Using Bayesian Methods to Augment the Interpretation of Critical Care Trials. An Overview of Theory and Example Reanalysis of the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial. Am J Respir Crit Care Med. 2021. PMID: 33270526. doi:10.1164/rccm.202006-2381CP
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。